Approvals· August 29, 2026 · 15 min read
Lisraya's DM Label: Boxed-Warning 30 mg Tablet, Table 3 Split, Unapproved 15 mg
By Ran Chen#FDA Approval#JAK Inhibitor#Dermatology
Topic
JAK Inhibitor
JAK inhibitor labels, boxed warnings, step therapy, immunology positioning, and access restrictions.
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Pricing & Access· August 13, 2026 · 22 min read
IBD Treatment Access (2026): Stelara & Humira Biosimilars Meet IL-23
Specialty· August 11, 2026 · 17 min read
Myelofibrosis Treatment Access Landscape: Jakafi, Vonjo, & Selinexor
By Ran Chen#Hematology#JAK Inhibitor#Specialty Pharmacy
Specialty· August 10, 2026 · 19 min read
Dermatomyositis Treatment Access (2026): Brepocitinib, Octagam IVIG, and DMARDs
Specialty· August 10, 2026 · 16 min read
Rheumatoid Arthritis Treatment Access (2026): Methotrexate, Biosimilars, and JAKs
Specialty· August 9, 2026 · 17 min read
Alopecia Areata Treatment Access (2026): Litfulo, Leqselvi, and Olumiant
Pricing & Access· July 16, 2026 · 23 min read
Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics
Evidence· June 14, 2026 · 12 min read
JAK inhibitors in FAERS: 242,498 adverse-event reports by the numbers
Pipeline· June 8, 2026 · 10 min read